CAJ | 학술논문

对2006年2月至2010年9月收治的70例年龄≥65岁接受厄洛替尼或吉非替尼治疗的晚期非小细胞肺癌患者的疗效及安全性进行回顾性分析.总有效率31.4％ (22/70),控制率84.3％ (59/70),中位无进展生存期8.0个月,中位生存期13.5个月(P＜0.05),1年生存率54.3％(38/70)；女性的有效率(42.8％)和控制率(94.3％)优于男性(20.0％和74.3％)(P＜0.05),非吸烟和体力状况＜2分者预后好；不良反应主要为轻度皮疹及腹泻.
대2006년2월지2010년9월수치적70례년령≥65세접수액락체니혹길비체니치료적만기비소세포폐암환자적료효급안전성진행회고성분석.총유효솔31.4％ (22/70),공제솔84.3％ (59/70),중위무진전생존기8.0개월,중위생존기13.5개월(P＜0.05),1년생존솔54.3％(38/70)；녀성적유효솔(42.8％)화공제솔(94.3％)우우남성(20.0％화74.3％)(P＜0.05),비흡연화체력상황＜2분자예후호；불량반응주요위경도피진급복사.
Seventy patients with advanced non-small-cell lung cancer (NSCLC) aged 65 or above were treated with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) erlotinib or gefitinib from February 2006 to September 2010. The efficacy and toxicities of treatment were retrospectively analyzed.The overall response rate and disease control rate were 31.4％ and 84.3％,respectively. Themedian progression-free survival time and median survival time were 8.0 months and 13.5 months,respectively(P ＜ 0.05 ). One-year survival rate was 54.3％. Response rate ( CR + PR) ( 42.9％ ) anddisease control rate (94.3％ )in female patients were superior to males (20.0％ and 74.3％ ) (P ＜ 0.05 ).Non-smoking and PS score ＜ 2 were good predictors for survival.The side effects were generally mild and mainly were skin rash and diarrhea.